MetaCap

BioNexus Gene Lab Corp (BGLC)

NASDAQ: BGLCHealth CareMedical SpecialitiesUSD

0.680.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BGLC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.26
52-week range
0.621 – 4.97
Day range
0.68 – 0.73
Volume / Avg
3.07K / 6.70K
Beta
—

52-week range

$0.621$4.97

BGLC stock today

BioNexus Gene Lab (BGLC) closed at $0.68 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 3.07K shares changing hands, about 46% of the average daily volume. At this level, BGLC sits near the bottom of its 52-week range of $0.621 to $4.97: 86.3% below the high and 9.5% above the low.

BioNexus Gene Lab has posted a net loss over the last twelve months (EPS of -$1.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BioNexus Gene Lab

Company profile

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process.

Industry
Medical Specialities
CEO
Mr. Su-Leng Tan
Headquarters
Kuala Lumpur
Employees
19

Financial highlights

Full financials

In fiscal 2025, BioNexus Gene Lab generated $7.4 million in revenue, down 21.9% from fiscal 2024, its first annual decline since 2024. BioNexus Gene Lab reported a net loss of $3.0 million, compared with a loss of $1.6 million a year earlier. Gross margin was 14.6% (up from 13.6%) and operating margin -39.9%.

BioNexus Gene Lab annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.42M$9.51M$9.77M$10.93M$13.36M
Growth-21.93%-2.66%-10.60%-18.21%+17.31%
Net income$-2.98M$-1.60M$-2.63M$-355.97K$751.57K
EPS (diluted)—$-0.09$-0.166——

Earnings

Earnings history
Last reported (Sep/2026)
Nov 19, 2026
EPS actual vs est.
$-0.39 vs —

BGLC news

All BGLC news

BioNexus Gene Lab peers

Health Care sector
BGLC peer companies
CompanyPrice% ChgMarket capCompare
ADVBAdvanced Biomed Inc.1.65-5.71%$2.73Mvs BGLC
ACONAclarion Inc.1.22-13.92%$3.52Mvs BGLC
AMSAmerican Shared Hospital Services1.00-4.76%$6.67Mvs BGLC
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs BGLC
SERASera Prognostics Inc. Class A1.81-4.23%$71.98Mvs BGLC
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs BGLC
XGNExagen Inc.3.61-5.00%$92.10Mvs BGLC
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs BGLC

Indexes, lists and sector

BioNexus Gene Lab stock FAQ

What is BioNexus Gene Lab's stock price today?

BGLC last traded at $0.68 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Who is BioNexus Gene Lab's CEO?

Mr. Su-Leng Tan is the chief executive officer of BioNexus Gene Lab Corp, which has about 19 employees.

What is the BGLC 52-week high?

The 52-week high for BGLC is $4.97 and the 52-week low is $0.621. The stock is currently 86.3% below its high.

Compare BGLC